Circular RNAs in non-alcoholic fatty liver disease: Functions and clinical significance

References

• Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic Steatohepatitis: a review. JAMA. 2020;323(12):1175–1183. doi: 10.1001/jama.2020.2298
   PubMed Web of Science ®Google Scholar
• Wang XJ, Malhi H. Nonalcoholic fatty liver disease. Ann Intern Med. 2018;169(9):ITC65–ITC80. doi: 10.7326/AITC201811060
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases. Hepatology. 2018;67(1):328–357. doi: 10.1002/hep.29367
   PubMed Web of Science ®Google Scholar
• Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic Steatohepatitis. Hepatology. 2019;69(6):2672–2682. doi: 10.1002/hep.30251
   PubMed Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. doi: 10.1038/nrgastro.2017.109
   PubMed Web of Science ®Google Scholar
• Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019;76(1):99–128. 10.1007/s00018-018-2947-0
   PubMed Web of Science ®Google Scholar
• Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537–2564. doi: 10.1016/j.cell.2021.04.015
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Rinella ME, Sanyal AJ, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology. 2021;73(3):1194–1198. doi: 10.1002/hep.31420
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi: 10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar
• Li Y, Zhao J, Yu S, et al. Extracellular vesicles long RNA sequencing reveals abundant mRNA, circRNA, and lncRNA in human blood as potential biomarkers for cancer diagnosis. Clin Chem. 2019;65(6):798–808. doi: 10.1373/clinchem.2018.301291
   PubMed Web of Science ®Google Scholar
• de Gonzalo-Calvo D, Vea A, Bar C, et al. Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: a novel tool for personalized medicine? Eur Heart J. 2019;40(20):1643–1650. doi: 10.1093/eurheartj/ehy234
   PubMed Web of Science ®Google Scholar
• Yu G, Yang Z, Peng T, et al. Circular RNAs: Rising stars in lipid metabolism and lipid disorders. J Cell Physiol. 2021;236(7):4797–4806. doi: 10.1002/jcp.30200
   PubMed Web of Science ®Google Scholar
• Meng S, Zhou H, Feng Z, et al. CircRNA: functions and properties of a novel potential biomarker for cancer. Mol Cancer. 2017;16(1):94. doi: 10.1186/s12943-017-0663-2
   PubMed Web of Science ®Google Scholar
• Jeck WR, Sorrentino JA, Wang K, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013;19(2):141–157. doi: 10.1261/rna.035667
   PubMed Web of Science ®Google Scholar
• Salzman J, Chen RE, Olsen MN, et al. Cell-type specific features of circular RNA expression. PLoS Genet. 2013;9(9):e1003777. doi: 10.1371/journal.pgen.1003777
   PubMed Web of Science ®Google Scholar
• Saaoud F, Drummer IVC, Shao Y, et al. Circular RNAs are a novel type of non-coding RNAs in ROS regulation, cardiovascular metabolic inflammations and cancers. Pharmacol Ther. 2021;220:107715. doi: 10.1016/j.pharmthera.2020.107715
   PubMed Web of Science ®Google Scholar
• Tang Y, Bao J, Hu J, et al. Circular RNA in cardiovascular disease: Expression, mechanisms and clinical prospects. J Cell Mol Med. 2021;25(4):1817–1824. doi: 10.1111/jcmm.16203
   PubMed Web of Science ®Google Scholar
• Mehta SL, Dempsey RJ, Vemuganti R. Role of circular RNAs in brain development and CNS diseases. Prog Neurobiol. 2020;186:101746. doi: 10.1016/j.pneurobio.2020.101746
   PubMed Web of Science ®Google Scholar
• Zhou Z, Sun B, Huang S, et al. Roles of circular RNAs in immune regulation and autoimmune diseases. Cell Death Dis. 2019;10(7):503 doi: 10.1038/s41419-019-1744-5
   PubMedGoogle Scholar
• Sanger HL, Klotz G, Riesner D, et al. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci U S A. 1976;73(11):3852–3856. doi: 10.1073/pnas.73.11.3852
   PubMed Web of Science ®Google Scholar
• Cocquerelle C, Mascrez B, Hetuin D, et al. Mis-splicing yields circular RNA molecules. FASEB J. 1993;7(1):155–160. doi: 10.1096/fasebj.7.1.7678559
   PubMed Web of Science ®Google Scholar
• Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333–338. doi: 10.1038/nature11928
   PubMed Web of Science ®Google Scholar
• Salzman J, Gawad C, Wang PL, et al. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS One. 2012;7(2):e30733 doi: 10.1371/journal.pone.0030733
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhang XO, Jiang T, et al. Comprehensive identification of alternative back-splicing in human tissue transcriptomes. Nucleic Acids Res. 2020;48(4):1779–1789. doi: 10.1093/nar/gkaa005
   PubMed Web of Science ®Google Scholar
• Li X, Yang L, Chen LL. The biogenesis, functions, and challenges of Circular RNAs. Mol Cell. 2018;71(3):428–442. doi: 10.1016/j.molcel.2018.06.034
   PubMed Web of Science ®Google Scholar
• Ivanov A, Memczak S, Wyler E, et al. Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. Cell Rep. 2015;10(2):170–177. doi: 10.1016/j.celrep.2014.12.019
   PubMed Web of Science ®Google Scholar
• Aktas T, Avsar Ilik I, Maticzka D, et al. DHX9 suppresses RNA processing defects originating from the Alu invasion of the human genome. Nature. 2017;544(7648):115–119. doi: 10.1038/nature21715
   PubMed Web of Science ®Google Scholar
• Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol. 2020;21(8):475–490. doi: 10.1038/s41580-020-0243-y
   PubMed Web of Science ®Google Scholar
• Conn SJ, Pillman KA, Toubia J, et al. The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015;160(6):1125–1134. doi: 10.1016/j.cell.2015.02.014
   PubMed Web of Science ®Google Scholar
• Han B, Chao J, Yao H. Circular RNA and its mechanisms in disease: from the bench to the clinic. Pharmacol Ther. 2018;187:31–44. doi: 10.1016/j.pharmthera.2018.01.010
   PubMed Web of Science ®Google Scholar
• Noto JJ, Schmidt CA, Matera AG. Engineering and expressing circular RNAs via tRNA splicing. RNA Biol. 2017;14(8):978–984. doi: 10.1080/15476286.2017.1317911
   PubMed Web of Science ®Google Scholar
• Maass PG, Glazar P, Memczak S, et al. A map of human circular RNAs in clinically relevant tissues. J Mol Med (Berl). 2017;95(11):1179–1189. doi: 10.1007/s00109-017-1582-9
   PubMed Web of Science ®Google Scholar
• Dong R, Ma XK, Chen LL, et al. Increased complexity of circRNA expression during species evolution. RNA Biol. 2017;14(8):1064–1074. doi: 10.1080/15476286.2016.1269999
   PubMed Web of Science ®Google Scholar
• Rybak-Wolf A, Stottmeister C, Glazar P, et al. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Mol Cell. 2015;58(5):870–885. doi: 10.1016/j.molcel.2015.03.027
   PubMed Web of Science ®Google Scholar
• Suzuki H, Zuo Y, Wang J, et al. Characterization of RNase R-digested cellular RNA source that consists of lariat and circular RNAs from pre-mRNA splicing. Nucleic Acids Res. 2006;34(8):e63 doi: 10.1093/nar/gkl151
   PubMed Web of Science ®Google Scholar
• Enuka Y, Lauriola M, Feldman ME, et al. Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor. Nucleic Acids Res. 2016;44(3):1370–1383. doi: 10.1093/nar/gkv1367
   PubMed Web of Science ®Google Scholar
• Zhou WY, Cai ZR, Liu J, et al. Circular RNA: metabolism, functions and interactions with proteins. Mol Cancer. 2020;19(1):172 doi: 10.1186/s12943-020-01286-3
   PubMed Web of Science ®Google Scholar
• Li Z, Huang C, Bao C, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015;22(3):256–264. doi: 10.1038/nsmb.2959
   PubMed Web of Science ®Google Scholar
• Conn VM, Hugouvieux V, Nayak A, et al. A circRNA from SEPALLATA3 regulates splicing of its cognate mRNA through R-loop formation. Nat Plants. 2017;3(5):17053 doi: 10.1038/nplants.2017.53
   PubMed Web of Science ®Google Scholar
• Ashwal-Fluss R, Meyer M, Pamudurti NR, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;56(1):55–66. doi: 10.1016/j.molcel.2014.08.019
   PubMed Web of Science ®Google Scholar
• Liu Y, Su H, Zhang J, et al. Back-spliced RNA from retrotransposon binds to centromere and regulates centromeric chromatin loops in maize. PLoS Biol. 2020;18(1):e3000582. doi: 10.1371/journal.pbio.3000582
   PubMed Web of Science ®Google Scholar
• Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384–388. doi: 10.1038/nature11993
   PubMed Web of Science ®Google Scholar
• Huang A, Zheng H, Wu Z, et al. Circular RNA-protein interactions: functions, mechanisms, and identification. Theranostics. 2020;10(8):3503–3517. doi: 10.7150/thno.42174
   PubMed Web of Science ®Google Scholar
• Pamudurti NR, Bartok O, Jens M, et al. Translation of CircRNAs. Mol Cell. 2017;66(1):9–21 e7. doi: 10.1016/j.molcel.2017.02.021
   PubMed Web of Science ®Google Scholar
• Lei M, Zheng G, Ning Q, et al. Translation and functional roles of circular RNAs in human cancer. Mol Cancer. 2020;19(1):30. doi: 10.1186/s12943-020-1135-7
   PubMed Web of Science ®Google Scholar
• Chen CK, Cheng R, Demeter J, et al. Structured elements drive extensive circular RNA translation. Mol Cell. 2021;81(20):4300–4318.e13. doi: 10.1016/j.molcel.2021.07.042
   PubMed Web of Science ®Google Scholar
• Yu J, Xu QG, Wang ZG, et al. Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma. J Hepatol. 2018;68(6):1214–1227. doi: 10.1016/j.jhep.2018.01.012
   PubMed Web of Science ®Google Scholar
• Li L, Guo J, Chen Y, et al. Comprehensive CircRNA expression profile and selection of key CircRNAs during priming phase of rat liver regeneration. BMC Genomics. 2017;18(1):80. doi: 10.1186/s12864-016-3476-6
   PubMed Web of Science ®Google Scholar
• Guo XY, He CX, Wang YQ, et al. Circular RNA profiling and bioinformatic modeling identify its regulatory role in hepatic steatosis. Biomed Res Int. 2017;2017:5936171. doi: 10.1155/2017/5936171
   PubMed Web of Science ®Google Scholar
• Yuan X, Diao J, Du A, et al. Circular RNA expression profiles and features in NAFLD mice: a study using RNA-seq data. J Transl Med. 2020;18(1):476. doi: 10.1186/s12967-020-02637-w
   PubMed Web of Science ®Google Scholar
• Guo J, Zhou Y, Cheng Y, et al. Metformin-induced changes of the coding transcriptome and non-coding RNAs in the livers of non-alcoholic fatty liver disease mice. Cell Physiol Biochem. 2018;45(4):1487–1505. doi: 10.1159/000487575
   PubMedGoogle Scholar
• Li P, Shan K, Liu Y, et al. CircScd1 promotes fatty liver disease via the Janus kinase 2/Signal Transducer and activator of transcription 5 pathway. Dig Dis Sci. 2019;64(1):113–122. doi: 10.1007/s10620-018-5290-2
   PubMed Web of Science ®Google Scholar
• Ou Q, Zhao Y, Zhou J, et al. Comprehensive circular RNA expression profiles in a mouse model of nonalcoholic steatohepatitis. Mol Med Rep. 2019;19:2636–2648. doi: 10.3892/mmr.2019.9935
   PubMed Web of Science ®Google Scholar
• Jin X, Feng CY, Xiang Z, et al. CircRNA expression pattern and circRNA-miRNA-mRNA network in the pathogenesis of nonalcoholic steatohepatitis. Oncotarget. 2016;7(41):66455–66467. doi: 10.18632/oncotarget.12186
   PubMedGoogle Scholar
• Zhu M, Li M, Zhou W, et al. Qianggan extract improved nonalcoholic steatohepatitis by modulating lncRna/circrna immune ceRNA networks. BMC Complement Altern Med. 2019;19(1):156 doi: 10.1186/s12906-019-2577-6
   PubMed Web of Science ®Google Scholar
• Fan Y, Zheng Y, Wang J, et al. Differential expression and bioinformatic analysis of circRNA in nonalcoholic steatohepatitis cirrhosis. Int J Clin Exp Pathol. 2020;13:2820–2830.
   PubMed Web of Science ®Google Scholar
• Du C, Shen L, Ma Z, et al. Bioinformatic Analysis of Crosstalk Between circRNA, miRNA, and Target Gene Network in NAFLD. Front Genet. 2021;12:671523. doi: 10.3389/fgene.2021.671523
   PubMed Web of Science ®Google Scholar
• Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov. 2016;15(4):249–274. doi: 10.1038/nrd.2015.3
   PubMed Web of Science ®Google Scholar
• Leung C, Rivera L, Furness JB, et al. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13(7):412–425. doi: 10.1038/nrgastro.2016.85
   PubMed Web of Science ®Google Scholar
• Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–1048. doi: 10.1016/j.metabol.2015.12.012
   PubMed Web of Science ®Google Scholar
• Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol. 2018;68(2):268–279. doi: 10.1016/j.jhep.2017.09.003
   PubMed Web of Science ®Google Scholar
• Mokan M, Galajda P. Primary and secondary insulin resistance. Vnitř Lék. 2019;65(4):264–272. doi: 10.36290/vnl.2019.045
   PubMedGoogle Scholar
• Korenblat KM, Fabbrini E, Mohammed BS, et al. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology. 2008;134(5):1369–1375. doi: 10.1053/j.gastro.2008.01.075
   PubMed Web of Science ®Google Scholar
• Cai H, Jiang Z, Yang X, et al. Circular RNA HIPK3 contributes to hyperglycemia and insulin homeostasis by sponging miR-192-5p and upregulating transcription factor forkhead box O1. Endocr J. 2020;67(4):397–408. doi: 10.1507/endocrj.EJ19-0271
   PubMed Web of Science ®Google Scholar
• Cheng Z, Guo S, Copps K, et al. Foxo1 integrates insulin signaling with mitochondrial function in the liver. Nat Med. 2009;15(11):1307–1311. doi: 10.1038/nm.2049
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu H, Li Y, et al. Circular RNA SAMD4A controls adipogenesis in obesity through the miR-138-5p/EZH2 axis. Theranostics. 2020;10(10):4705–4719. doi: 10.7150/thno.42417
   PubMed Web of Science ®Google Scholar
• Alves-Bezerra M, Cohen DE. Triglyceride metabolism in the liver. Compr Physiol. 2017;8:1–8. doi: 10.1002/cphy.c170012
   PubMed Web of Science ®Google Scholar
• Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75(18):3313–3327. doi: 10.1007/s00018-018-2860-6
   PubMed Web of Science ®Google Scholar
• Guo XY, Chen JN, Sun F, et al. circRNA_0046367 prevents hepatoxicity of lipid peroxidation: An inhibitory role against hepatic steatosis. Oxid Med Cell Longev. 2017;2017:3960197. doi: 10.1155/2017/3960197
   PubMed Web of Science ®Google Scholar
• Guo XY, Sun F, Chen JN, et al. circRNA_0046366 inhibits hepatocellular steatosis by normalization of PPAR signaling. World J Gastroenterol. 2018;24(3):323–337. doi: 10.3748/wjg.v24.i3.323
   PubMed Web of Science ®Google Scholar
• Chen X, Tan QQ, Tan XR, et al. Circ_0057558 promotes nonalcoholic fatty liver disease by regulating ROCK1/AMPK signaling through targeting miR-206. Cell Death Dis. 2021;12(9):809 doi: 10.1038/s41419-021-04090-z
   PubMed Web of Science ®Google Scholar
• Zhu Y, Gui W, Lin X, et al. Knock-down of circular RNA H19 induces human adipose-derived stem cells adipogenic differentiation via a mechanism involving the polypyrimidine tract-binding protein 1. Exp Cell Res. 2020;387(2):111753 doi: 10.1016/j.yexcr.2019.111753
   PubMed Web of Science ®Google Scholar
• Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci. 2013;14(10):20704–20728. doi: 10.3390/ijms141020704
   PubMed Web of Science ®Google Scholar
• Chen Z, Tian R, She Z, et al. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med. 2020;152:116–141. doi: 10.1016/j.freeradbiomed.2020.02.025
   PubMed Web of Science ®Google Scholar
• Yang W, Zhao J, Zhao Y, et al. Hsa_circ_0048179 attenuates free fatty acid-induced steatosis via hsa_circ_0048179/miR-188-3p/GPX4 signaling. Aging. 2020;12(23):23996–24008. doi: 10.18632/aging.104081
   PubMedGoogle Scholar
• Li Y, Gao X, Wang Z, et al. RETRACTED: circular RNA 4099 aggravates hydrogen peroxide-induced injury by down-regulating microRNA-706 in L02 cells. Life Sci. 2020;241:116826. doi: 10.1016/j.lfs.2019.116826
   PubMed Web of Science ®Google Scholar
• Zhao Q, Liu J, Deng H, et al. Targeting Mitochondria-Located circRNA SCAR Alleviates NASH via Reducing mROS Output. Cell. 2020;183(1):76–93 e22. doi: 10.1016/j.cell.2020.08.009
   PubMed Web of Science ®Google Scholar
• Schuster S, Cabrera D, Arrese M, et al. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15(6):349–364. doi: 10.1038/s41575-018-0009-6
   PubMed Web of Science ®Google Scholar
• Albhaisi S, Noureddin M. Current and potential therapies targeting inflammation in NASH. Front Endocrinol. 2021;12:767314. doi: 10.3389/fendo.2021.767314
   PubMed Web of Science ®Google Scholar
• Jin X, Gao J, Zheng R, et al. Antagonizing circRNA_002581–miR-122–CPEB1 axis alleviates NASH through restoring PTEN–AMPK–mTOR pathway regulated autophagy. Cell Death Dis. 2020;11(2):123 doi: 10.1038/s41419-020-2293-7
   PubMed Web of Science ®Google Scholar
• Azzu V, Vacca M, Virtue S, et al. Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in nonalcoholic fatty liver disease. Gastroenterology. 2020;158(7):1899–1912. doi: 10.1053/j.gastro.2019.12.054
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang T, Feng R, et al. circARF3 alleviates mitophagy-mediated inflammation by targeting miR-103/TRAF3 in mouse adipose tissue. Mol Ther Nucleic Acids. 2019;14:192–203. doi: 10.1016/j.omtn.2018.11.014
   PubMedGoogle Scholar
• Lackner C, Tiniakos D. Fibrosis and alcohol-related liver disease. J Hepatol. 2019;70(2):294–304. doi: 10.1016/j.jhep.2018.12.003
   PubMed Web of Science ®Google Scholar
• Affo S, Yu LX, Schwabe RF. The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu Rev Pathol. 2017;12(1):153–186. doi: 10.1146/annurev-pathol-052016-100322
   PubMed Web of Science ®Google Scholar
• Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021;18(3):151–166. doi: 10.1038/s41575-020-00372-7
   PubMed Web of Science ®Google Scholar
• Liu W, Feng R, Li X, et al. TGF-β- and lipopolysaccharide-induced upregulation of circular RNA PWWP2A promotes hepatic fibrosis via sponging miR-203 and miR-223. Aging. 2019;11(21):9569–9580. doi: 10.18632/aging.102405
   PubMedGoogle Scholar
• Chen Y, Yuan B, Chen G, et al. Circular RNA RSF1 promotes inflammatory and fibrotic phenotypes of irradiated hepatic stellate cell by modulating miR-146a-5p. J Cell Physiol. 2020;235(11):8270–8282. doi: 10.1002/jcp.29483
   PubMed Web of Science ®Google Scholar
• Chen X, Li HD, Bu FT, et al. Circular RNA circFBXW4 suppresses hepatic fibrosis via targeting the miR-18b-3p/FBXW7 axis. Theranostics. 2020;10(11):4851–4870. doi: 10.7150/thno.42423
   PubMed Web of Science ®Google Scholar
• Yang YR, Hu S, Bu FT, et al. Circular RNA CREBBP suppresses hepatic fibrosis via targeting the hsa-miR-1291/LEFTY2 axis. Front Pharmacol. 2021;12:741151. doi: 10.3389/fphar.2021.741151
   PubMed Web of Science ®Google Scholar
• Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223–238. doi: 10.1038/s41575-020-00381-6
   PubMed Web of Science ®Google Scholar
• Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol. 2021;75(6):1476–1484. doi: 10.1016/j.jhep.2021.08.012
   PubMed Web of Science ®Google Scholar
• Liang WC, Wong CW, Liang PP, et al. Translation of the circular RNA circβ-catenin promotes liver cancer cell growth through activation of the wnt pathway. Genome Biol. 2019;20(1):84 doi: 10.1186/s13059-019-1685-4
   PubMed Web of Science ®Google Scholar
• Xu J, Ji L, Liang Y, et al. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduct Target Ther. 2020;5(1):298 doi: 10.1038/s41392-020-00375-5
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53(6):1874–1882. doi: 10.1002/hep.24268
   PubMed Web of Science ®Google Scholar
• Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(5):1264–1281 e4. doi: 10.1053/j.gastro.2018.12.036
   PubMed Web of Science ®Google Scholar
• Suzuki A, Diehl AM. Nonalcoholic Steatohepatitis. Annu Rev Med. 2017;68(1):85–98. doi: 10.1146/annurev-med-051215-031109
   PubMedGoogle Scholar
• Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–1554. doi: 10.1002/hep.27368
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology. 2018;155(2):443–457 e17. doi: 10.1053/j.gastro.2018.04.034
   PubMed Web of Science ®Google Scholar
• Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017;13(9):509–520. doi: 10.1038/nrendo.2017.56
   PubMed Web of Science ®Google Scholar
• Hedjazifar S, Khatib Shahidi R, Hammarstedt A, et al. The novel Adipokine Gremlin 1 antagonizes insulin action and is increased in type 2 diabetes and NAFLD/NASH. Diabetes. 2020;69(3):331–341. doi: 10.2337/db19-0701
   PubMed Web of Science ®Google Scholar
• Hu J, Wang H, Li X, et al. Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder. Theranostics. 2020;10(21):9702–9720. doi: 10.7150/thno.44297
   PubMed Web of Science ®Google Scholar
• Feldstein AE, Wieckowska A, Lopez AR, et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009;50(4):1072–1078. doi: 10.1002/hep.23050
   PubMed Web of Science ®Google Scholar
• Tamimi TI, Elgouhari HM, Alkhouri N, et al. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol. 2011;54(6):1224–9. doi: 10.1016/j.jhep.2010.08.023
   PubMed Web of Science ®Google Scholar
• Banasch M, Ellrichmann M, Tannapfel A, et al. The noninvasive (13)C-methionine breath test detects hepatic mitochondrial dysfunction as a marker of disease activity in non-alcoholic steatohepatitis. Eur J Med Res. 2011;16(6):258–64. doi: 10.1186/2047-783x-16-6-258
   PubMed Web of Science ®Google Scholar
• Hendrikx T, Walenbergh SM, Jeurissen ML, et al. Plasma IL-1 receptor antagonist levels correlate with the development of non-alcoholic steatohepatitis. Biomarker Med. 2015;9(12):1301–1309. doi: 10.2217/bmm.15.71
   PubMed Web of Science ®Google Scholar
• Tanwar S, Trembling PM, Guha IN, et al. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology. 2013;57(1):103–111. doi: 10.1002/hep.26030
   PubMed Web of Science ®Google Scholar
• Caussy C, Bhargava M, Villesen IF, et al. Collagen formation assessed by N-Terminal propeptide of type 3 procollagen is a heritable trait and is associated with liver fibrosis assessed by magnetic resonance elastography. Hepatology. 2019;70(1):127–141. doi: 10.1002/hep.30610
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E, Chalasani N. Noninvasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68(2):305–315. doi: 10.1016/j.jhep.2017.11.013
   PubMed Web of Science ®Google Scholar
• Koehler EM, Schouten JN, Hansen BE, et al. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol. 2013;11(9):1201–4. doi: 10.1016/j.cgh.2012.12.031
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503–508. doi: 10.1016/j.dld.2009.08.002
   PubMedGoogle Scholar
• Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137(3):865–872. doi: 10.1053/j.gastro.2009.06.005
   PubMed Web of Science ®Google Scholar
• Mozes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of noninvasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71(5):1006–1019. doi: 10.1136/gutjnl-2021-324243
   PubMed Web of Science ®Google Scholar
• Anstee QM, Lawitz EJ, Alkhouri N, et al. Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials. Hepatology. 2019;70(5):1521–1530. doi: 10.1002/hep.30842
   PubMed Web of Science ®Google Scholar
• Li J, Qi J, Tang Y, et al. A nanodrug system overexpressed circRNA_0001805 alleviates nonalcoholic fatty liver disease via miR-106a-5p/miR-320a and ABCA1/CPT1 axis. J Nanobiotechnology. 2021;19(1):363 doi: 10.1186/s12951-021-01108-8
   PubMed Web of Science ®Google Scholar
• Xu YX, Pu SD, Li X, et al. Exosomal ncRnas: novel therapeutic target and biomarker for diabetic complications. Pharmacol Res. 2022;178:106135. doi: 10.1016/j.phrs.2022.106135
   PubMed Web of Science ®Google Scholar
• Li C, Ni YQ, Xu H, et al. Roles and mechanisms of exosomal non-coding RNAs in human health and diseases. Signal Transduct Target Ther. 2021;6(1):383 doi: 10.1038/s41392-021-00779-x
   PubMed Web of Science ®Google Scholar
• Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478). doi: 10.1126/science.aau6977
   PubMed Web of Science ®Google Scholar
• Mathieu M, Martin-Jaular L, Lavieu G, et al. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol. 2019;21(1):9–17. doi: 10.1038/s41556-018-0250-9
   PubMed Web of Science ®Google Scholar
• Zhang X, Yuan X, Shi H, et al. Exosomes in cancer: small particle, big player. J Hematol Oncol. 2015;8(1):83 doi: 10.1186/s13045-015-0181-x
   PubMedGoogle Scholar
• Cheng W, Wang K, Zhao Z, et al. Exosomes-mediated transfer of miR-125a/b in cell-to-cell communication: a novel mechanism of genetic exchange in the intestinal microenvironment. Theranostics. 2020;10(17):7561–7580. doi: 10.7150/thno.41802
   PubMed Web of Science ®Google Scholar
• Yang H, Zhang H, Yang Y, et al. Hypoxia induced exosomal circRNA promotes metastasis of colorectal cancer via targeting GEF-H1/RhoA axis. Theranostics. 2020;10(18):8211–8226. doi: 10.7150/thno.44419
   PubMed Web of Science ®Google Scholar
• Villarroya-Beltri C, Gutierrez-Vazquez C, Sanchez-Cabo F, et al. Sumoylated hnRNPA2B1 controls the sorting of miRnas into exosomes through binding to specific motifs. Nat Commun. 2013;4(1):2980 doi: 10.1038/ncomms3980
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Shenoda BB, Lin Z, et al. Inflammation potentiates miR-939 expression and packaging into small extracellular vesicles. J Extracell Vesicles. 2019;8(1):1650595 doi: 10.1080/20013078.2019.1650595
   PubMed Web of Science ®Google Scholar
• Qu L, Ding J, Chen C, et al. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. Cancer Cell. 2016;29(5):653–668. doi: 10.1016/j.ccell.2016.03.004
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang X, Li C, et al. Circular RNA profiling provides insights into their subcellular distribution and molecular characteristics in HepG2 cells. RNA Biol. 2019;16(2):220–232. doi: 10.1080/15476286.2019.1565284
   PubMed Web of Science ®Google Scholar
• Garcia-Martin R, Wang G, Brandao BB, et al. MicroRNA sequence codes for small extracellular vesicle release and cellular retention. Nature. 2022;601(7893):446–451. doi: 10.1038/s41586-021-04234-3
   PubMed Web of Science ®Google Scholar
• Li Y, Zheng Q, Bao C, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 2015;25(8):981–984. doi: 10.1038/cr.2015.82
   PubMed Web of Science ®Google Scholar
• Piwecka M, Glazar P, Hernandez-Miranda LR, et al. Loss of a mammalian circular RNA locus causes miRNA deregulation and affects brain function. Science. 2017;357(6357). doi: 10.1126/science.aam8526
   PubMed Web of Science ®Google Scholar
• Villarroya-Beltri C, Baixauli F, Gutierrez-Vazquez C, et al. Sorting it out: regulation of exosome loading. Semin Cancer Biol. 2014;28:3–13. doi: 10.1016/j.semcancer.2014.04.009
   PubMed Web of Science ®Google Scholar
• Liu CH, Ampuero J, Gil-Gomez A, et al. miRNAs in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2018;69(6):1335–1348. doi: 10.1016/j.jhep.2018.08.008
   PubMed Web of Science ®Google Scholar
• Chen W, Quan Y, Fan S, et al. Exosome-transmitted circular RNA hsa_circ_0051443 suppresses hepatocellular carcinoma progression. Cancer Lett. 2020;475:119–128. doi: 10.1016/j.canlet.2020.01.022
   PubMed Web of Science ®Google Scholar
• Bai H, Lei K, Huang F, et al. Exo-circRNAs: a new paradigm for anticancer therapy. Mol Cancer. 2019;18(1):56 doi: 10.1186/s12943-019-0986-2
   PubMedGoogle Scholar
• He AT, Liu J, Li F, et al. Targeting circular RNAs as a therapeutic approach: current strategies and challenges. Signal Transduct Target Ther. 2021;6(1):185 doi: 10.1038/s41392-021-00569-5
   PubMed Web of Science ®Google Scholar
• Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50(1):259–293. doi: 10.1146/annurev.pharmtox.010909.105654
   PubMedGoogle Scholar
• Jiang Q, Liu C, Li CP, et al. Circular RNA-ZNF532 regulates diabetes-induced retinal pericyte degeneration and vascular dysfunction. J Clin Invest. 2020;130(7):3833–3847. doi: 10.1172/JCI123353
   PubMed Web of Science ®Google Scholar
• Li S, Li X, Xue W, et al. Screening for functional circular RNAs using the CRISPR–Cas13 system. Nat Methods. 2021;18(1):51–59. doi: 10.1038/s41592-020-01011-4
   PubMed Web of Science ®Google Scholar
• Li S, Wu H, Chen LL. Screening circular RNAs with functional potential using the RfxCas13d/BSJ-gRNA system. Nat Protoc. 2022;17(9):2085–2107. doi: 10.1038/s41596-022-00715-5
   PubMed Web of Science ®Google Scholar
• Lin X, Du Y, Lu W, et al. CircRNF111 protects against insulin resistance and lipid deposition via regulating miR-143-3p/IGF2R axis in metabolic syndrome. Front Cell Dev Biol. 2021;9:663148. doi: 10.3389/fcell.2021.663148
   PubMed Web of Science ®Google Scholar
• Zhang H, Deng T, Ge S, et al. RETRACTED ARTICLE: exosome circRNA secreted from adipocytes promotes the growth of hepatocellular carcinoma by targeting deubiquitination-related USP7. Oncogene. 2019;38(15):2844–2859. doi: 10.1038/s41388-018-0619-z
   PubMed Web of Science ®Google Scholar
• Cai W, Wang J, Chu C, et al. Metal–Organic Framework-Based Stimuli-Responsive Systems for Drug Delivery. Adv Sci. 2019;6(1):1801526 doi: 10.1002/advs.201801526
   Web of Science ®Google Scholar
• Semcheddine F, El Islem Guissi N, Liu W, et al. Rapid and label-free cancer theranostics via in situ bio-self-assembled DNA–gold nanostructures loaded exosomes. Mater Horiz. 2021;8(10):2771–2784. doi: 10.1039/d1mh00880c
   PubMed Web of Science ®Google Scholar
• Litke JL, Jaffrey SR. Highly efficient expression of circular RNA aptamers in cells using autocatalytic transcripts. Nat Biotechnol. 2019;37(6):667–675. doi: 10.1038/s41587-019-0090-6
   PubMed Web of Science ®Google Scholar
• Liu CX, Chen LL. Circular RNAs: Characterization, cellular roles, and applications. Cell. 2022;185(12):2016–2034. doi: 10.1016/j.cell.2022.04.021
   PubMed Web of Science ®Google Scholar
• Huang C, Liang D, Tatomer DC, et al. A length-dependent evolutionarily conserved pathway controls nuclear export of circular RNAs. Genes Dev. 2018;32(9–10):639–644. doi: 10.1101/gad.314856.118
   PubMed Web of Science ®Google Scholar
• Zhang L, Hou C, Chen C, et al. The role of N(6)-methyladenosine (m(6)A) modification in the regulation of circRNAs. Mol Cancer. 2020;19(1):105 doi: 10.1186/s12943-020-01224-3
   PubMed Web of Science ®Google Scholar
• Chen YG, Chen R, Ahmad S, et al. N6-methyladenosine modification controls Circular RNA immunity. Mol Cell. 2019;76(1):96–109 e9. doi: 10.1016/j.molcel.2019.07.016
   PubMed Web of Science ®Google Scholar
• Chen RX, Chen X, Xia LP, et al. N(6)-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis. Nat Commun. 2019;10(1):4695 doi: 10.1038/s41467-019-12651-2
   PubMed Web of Science ®Google Scholar
• Chen X, Yang T, Wang W, et al. Circular RNAs in immune responses and immune diseases. Theranostics. 2019;9(2):588–607. doi: 10.7150/thno.29678
   PubMed Web of Science ®Google Scholar
• Qu L, Yi Z, Shen Y, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell. 2022;185(10):1728–1744 e16. doi: 10.1016/j.cell.2022.03.044
   PubMed Web of Science ®Google Scholar